Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any classic complement early component deficiency in which the cause of the disease is a mutation in the C9 gene.
Features include: Decreased circulating complement C9 concentration.
C9 encodes complement C9 (559 aa). Pore-forming component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis. Highest expression in Liver (404.9 TPM) and Testis (1.3 TPM).
Complement component 9 deficiency is associated with mutations in the C9 gene on chromosome 5.
The C9 protein participates in C5b:C6:C7, C8, C9, CLU:C5b:C6:C7, C8, C9, and Formation of soluble VTN:C5b-C9 pathways.
C9 is classified as a druggable target (Druggable Genome category) with score 1.1.
Genetic testing for C9 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for complement component 9 deficiency.
4 publications have been identified in PubMed for complement component 9 deficiency. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Zheng G (2026). [PMID: 41781919](https://pubmed.ncbi.nlm.nih.gov/41781919/). *BMC Pediatr*. [Case Report / Case Series]
Ohlsson C (2026). [PMID: 41925863](https://pubmed.ncbi.nlm.nih.gov/41925863/). *Calcif Tissue Int*. [Basic Science / Preclinical]
Martinez T (2026). [PMID: 41980333](https://pubmed.ncbi.nlm.nih.gov/41980333/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Guo Z (2024). [PMID: 39500113](https://pubmed.ncbi.nlm.nih.gov/39500113/). *Atherosclerosis*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:52 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about complement component 9 deficiency